Actively Recruiting
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
Led by University Hospital, Grenoble · Updated on 2024-08-30
30
Participants Needed
2
Research Sites
182 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Grenoble
Lead Sponsor
U
University Hospital, Marseille
Collaborating Sponsor
AI-Summary
What this Trial Is About
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage. Dysfunction of proteins initially known to initiate the classical pathway for complement activation (C1q and C1s), and their functional interference with the multifunctional protein HMGB1 (High-Mobility Group Box 1), appears to be associated with SLE. On the other hand, C1s, HMGB1 and C1q can be targeted by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies from lupus patients, whose functional impact remains to be explored, in particular for non-canonical functions, independent of the complement activation cascade. Studies are needed to investigate the pathogenic role of these autoantibodies in SLE, including possible interference with the inactivation of HMGB1. This project plans to investigate the role of anti-C1s, anti-HMGB1 and anti-C1q autoantibodies in the pathogenesis of Systemic Lupus Erythematosus. This pilot study will be performed for 30 patients with active SLE on serum, realized for routine patient care. The investigators will identify the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum. The investigators will also explore the functional role of these purified autoantibodies.
CONDITIONS
Official Title
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years old
- Weight 63 40 Kg
- Patients who have valid health insurance
- Patients with lupus diagnosis criteria (EULAR-ACR-2019)
- Active lupus nephritis defined by SLEDAI score >5 and joint and/or kidney involvement.
You will not qualify if you...
- Patients protected by law (minors, pregnant or breastfeeding women, subjects under guardianship or curatorship, deprived of liberty or enforced hospitalized, under administrative or judicial supervision)
- Patients on dialysis or on plasma exchange.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHU Grenoble Alpes
Grenoble, France, 38043
Actively Recruiting
2
AP-HM_Hôpital de la Conception
Marseille, France, 13005
Actively Recruiting
Research Team
C
Chantal DUMESTRE-PERARD, Professor
CONTACT
G
Giovanna CLAVARINO, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here